The U.S. Food and Drug Administration (FDA) has given Plus Therapeutics Inc. a Fast Track Designation for Rhenium-186 NanoLiposome (186 RNL), a novel drug for the treatment of leptomeningeal metastases (LM). As a rare complication of cancer, LM primarily occurs with diagnoses of breast cancer, lung cancer, and melanomas when the cancer spreads to the meninges (membranes) of the central nervous system. Recently, Plus Therapeutics Inc. announced Investigational New Drug (IND) application clearance from the FDA and is planning to begin patient recruitment for its ReSPECT-LM clinical trial, a sequential cohort, single dose, dose escalation Phase 1 study. As a clinical-stage pharmaceutical company, Plus Therapeutics, Inc Is committed to complex and novel drug development, manufacture, and commercialization for patients battling cancer and other life-threatening diseases.
Read more here.